Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
Latest Information Update: 21 May 2022
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Expanded access; Therapeutic Use
- Sponsors Cara Therapeutics
- 11 May 2022 Status changed from recruiting to completed.
- 09 Sep 2021 New trial record